Gapping up
Other news:
- CMRX +4% (submits Dordaviprone NDA for Accelerated Approval to FDA)
- PSIX +3.5% (uplisted its common stock to the Nasdaq Stock Market and began trading on that market; will continue to trade under the symbol PSIX)
- IDYA +3.3% (enters exclusive license with Hengrui Pharma for SHR-4849)
- MHLD +3.2% (Maiden Holdings and Kestrel Group enter combination agreement)
- AR +3.1% (positive Barron's article)
- TC +3% (files for 761,719 ADS offering by selling shareholder)
- EQT +2.9% (positive Barron's article)
- SLND +2.9% (announces $20 million conversion of promissory notes due to management to common stock)
- RLX +1.4% (MSCI ESG Rating Upgraded to "AA", Achieving the Highest Rating in the Global Tobacco Industry)
- ERJ +1.4% (announces a firm order for six A-29 Super Tucanos from an undisclosed customer)
- HALO +1.3% (announces FDA approval of Bristol Myers Squibb's (BMY) Opdivo Qvantig with Enhanze for subcutaneous use in most previously approved adult solid tumor Opdivo indications; announces argenx's VYDURA with ENHANZE was granted regulatory approval in Japan for chronic inflammatory demyelinating polyneuropathy; announces Takeda (TAK) received regulatory approval for HYQVIA 10% subcutaneous injection set with ENHANZE in Japan for patients with agammaglobulinemia or hypogammaglobulinemia)
Analyst comments:
- ARTV +5.2% (initiated with a Buy at H.C. Wainwright)
- NUVL +0.7% (initiated with a Buy at H.C. Wainwright)
- AAL +0.6% (upgraded to Outperform from Mkt Perform at Raymond James)